CATX: רווח למניה בשנים עשר החודשים האחרונים perspectivetherapeutics.com

Perspective Therapeutics (CATX) currently generates no operating income, relying instead on external investments. The rolling earnings per share metric confirms financial volatility, with the parameter value equal to -1.25. The path forward lies in the development of the targeted alpha therapy platform and new contracts with pharma behemoths. In-house logistics for rare isotopes create a formidable technological barrier, strengthening the company's market position.

For Perspective Therapeutics (CATX), which is developing high-precision radiopharmaceutical cancer therapy, this indicator serves as a measure of how effectively innovation is capitalized into actual revenue. By analyzing the 12-month net income per share trend, an investor sees the result of dividing total net income by the number of securities, allowing for an objective assessment of the return on a unit of shareholder equity.